Abstract
International consensus guidelines for the management of pancreatic intraductal papillary mucinous neoplasm (IPMN) were revised in 2012. The most important difference between the first and revised editions is an algorithmic change about the treatment policy for branch duct (BD)-IPMN. The first edition recommended the algorithm in which cyst size was of great importance. However, in the revised edition, both high-risk stigmata and worrisome features are recognized as findings indicating the suspicion of malignancy more than cyst size. On the other hand, it was recommended that the term carcinoma in situ be abandoned according to the recent WHO classification, and that the term high-grade dysplasia be used. The usefulness of the revised edition should be validated in the future. It will be necessary to revise the guidelines further based on new evidence.
